Dr Peter Connick
Consultant Neurologist & Honorary Clinical Senior Lecturer
- Centre for Clinical Brain Sciences
- Euan MacDonald Centre for Motor Neurone Disease Research
- Anne Rowling Regenerative Neurology Clinic
Contact details
- Email: pconnick@exseed.ed.ac.uk
Background
I'm an academic neurologist who trained in Cambridge and London before taking my current position at the University of Edinburgh, Anne Rowling Regenerative Neurology Clinic.
Qualifications
Doctor of Philosophy (PhD), University of Cambridge:Autologous mesenchymal stem cells as a neuroprotective therapy for secondary progressive multiple sclerosis
Bachelor of Medicine and Bachelor of Surgery, University of Glasgow
Bachelor of Science, University of Glasgow
Research summary
The big challenge in 21st century neurology is to develop treatments that can slow, stop, or reverse the loss of brain cells in neurodegenerative diseases like the dementias, motor neurone disease, and MS.
Part of the reason why we don't already have these treatments is because we lack the tools to measure neuroprotection and brain repair in clinical trials. My work aims to develop the measurement tools we need.
Separately, by defining diseases through their symptoms rather than through the underlying (patho)biology, most patients in any regenerative neurology trial will have little prospect of benefit. I also work on methods to ""stratify" neurodegenerative diseases so that the right person gets the right treatment at the right time.
Research Interests
Regenerative neurology spanning two principal themes. First: developing and improving existing techniques to measure the impact of regenerative therapies in brain diseases, and second: developing techniques to stratify phenomenologically defined patient groups according to the undelying pathology - i.e. stratified medicine in the neurodegenerative disorders.
Related links
Research into neurodegenerative conditions at the Centre for Clinical Brain Sciences
Clinical research & trials at the Centre for Clinical Brain Sciences
-
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
In:
Lancet Neurology, vol. 20, pp. 709-720
DOI: https://doi.org/10.1016/S1474-4422(21)00179-4
Research output: Contribution to Journal › Article (Published) -
iPSC-derived myelinoids to study myelin biology of humans
In:
Developmental Cell, vol. 56, pp. 1346-1358.e6
DOI: https://doi.org/10.1016/j.devcel.2021.04.006
Research output: Contribution to Journal › Article (Published) -
MS-SMART study: systematic sampling bias concerns - Authors' reply
(2 pages)
In:
Lancet Neurology, vol. 19, pp. 479-480
DOI: https://doi.org/10.1016/S1474-4422(20)30149-6
Research output: Contribution to Journal › Letter (Published) -
Systematic review of prediction models in relapsing remitting multiple sclerosis
In:
PLoS ONE, vol. 15, pp. e0233575
DOI: https://doi.org/10.1371/journal.pone.0233575
Research output: Contribution to Journal › Article (Published) -
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
In:
Efficacy and Mechanism Evaluation, vol. 7, pp. 1-72
DOI: https://doi.org/10.3310/eme07030
Research output: Contribution to Journal › Article (Published)